Assessing the socio-economic burden of inherited and inflammatory neuromuscular diseases (BIND study): a study protocol
Authors:
- Ian C. SmithISIan C. Smith
- Yasmin AbusetahYAYasmin Abusetah
- Homira OsmanHOHomira Osman
- Aditi GargAGAditi Garg
- Alyssa GrantAGAlyssa Grant
- Hanns LochmullerHLHanns Lochmuller
- Hugh McMillanHMHugh McMillan
- Gerald PfefferGPGerald Pfeffer
- Lawrence KorngutLKLawrence Korngut
- Cynthia GagnonCGCynthia Gagnon
- Daria WojtalDWDaria Wojtal
Open Access
- 6 August 2025
- journal article
- research article
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 20 (1) , 1-16
Abstract
Introduction: Neuromuscular diseases (NMDs) are rare multisystem, genetic or acquired disorders causing weakness and/or sensory loss. It is essential for governments, insurance providers, and broader society to have a better understanding of the burden of illness of NMDs. Our goal is to assess the social and economic burden of Canadians living with NMDs, encompassing schooling and education achievement, health-related quality-of-life, and labour force participation and productivity. Methods and analysis: We will conduct a national, cross-sectional survey of individuals living with a NMD and their caregivers who are members of Muscular Dystrophy Canada and/or are patients within our national network of neuromuscular clinics. Surveys can be completed online or via telephone. The specific sub-sections of the questionnaire will differ based on respondent’s profile, whether they are 1) a minor living with a NMD, 2) an adult living with a NMD, 3) an adult who is a caregiver for someone living with a NMD, or 4) an adult who both lives with a NMD and is a caregiver for someone with a NMD. We will use descriptive statistics to describe distributions and ranges of the social and economic measures. Pearson correlations for continuous data and Spearman rho for rank data will be used to detect the strength of association of socio-demographic factors, disease characteristics, and social and economic impacts of NMDs. Ethics and dissemination: The study protocol has been approved by the Ottawa Health Science Network Research Ethics Board (Protocol ID # 20210601-01H). This study will provide the overall impact of NMD on costs and health-related quality of life, disseminated via a series of manuscripts which will include both between- and within-NMD/NMD subtype comparisons. The data obtained will guide governmental policy development and inform patient organisation programs to deliver more effective supports to individuals and families affected by NMDs.Keywords
Funding Information
- Canadian Institutes of Health Research (178534, INS-464765, FDN-167281, ERT-174211, OR2-189333)
- Canada Foundation for Innovation (CFI-JELF 38412)
- Canada Research Chairs (950-232279)
- European Commission (101080249)
- Canada Research Coordinating Committee (NFRFG-2022-00033)
- Canada First Research Excellence Fund (CFREF-2022-00007)
- Physicians' Services Incorporated Foundation (19-28)
- Muscular Dystrophy Canada (932196)
This publication has 66 references indexed in Scilit:
- Labor market participation and productivity costs for female caregivers of minor male children with Duchenne and Becker muscular dystrophiesMuscle & Nerve, 2021
- Improvements in health status and utility associated with ataluren for the treatment of nonsense mutation Duchenne muscular dystrophyMuscle & Nerve, 2019
- Standardized Questionnaire for the Measurement, Valuation, and Estimation of Costs of Informal Care Based on the Opportunity Cost and Proxy Good MethodApplied Health Economics and Health Policy, 2018
- Hyperckemia and myalgia are common presentations of anoctamin‐5‐related myopathy in French patientsMuscle & Nerve, 2017
- The development of a financial toxicity patient‐reported outcome in cancer: The COST measureCancer, 2014
- Cost of illness for neuromuscular diseases in the United StatesMuscle & Nerve, 2013
- Exploring Employment in Consultation Reports of Patients With Neuromuscular DiseasesArchives of Physical Medicine and Rehabilitation, 2012
- Socioeconomic burden of amyotrophic lateral sclerosis, myasthenia gravis and facioscapulohumeral muscular dystrophyJournal of Neurology, 2009
- The friction cost method for measuring indirect costs of diseaseJournal of Health Economics, 1995
- Reliability of the Health Utilities Index—Mark III used in the 1991 cycle 6 Canadian General Social Survey Health QuestionnaireQuality of Life Research, 1995